Evaluation and optimization of a commercial enzyme linked immunosorbent assay for detection of Chlamydophila pneumoniae IgA antibodies by Frikha-Gargouri, Olfa et al.
BioMed  Central
Page 1 of 8
(page number not for citation purposes)
BMC Infectious Diseases
Open Access Research article
Evaluation and optimization of a commercial enzyme linked 
immunosorbent assay for detection of Chlamydophila pneumoniae 
IgA antibodies
Olfa Frikha-Gargouri1, Radhouane Gdoura1, Abir Znazen1, Nozha Ben Arab2, 
Jalel Gargouri3, Mounir Ben Jemaa2 and Adnene Hammami*1
Address: 1Department of Microbiology and research laboratory "Microorganismes et Pathologie Humaine", Habib Bourguiba Hospital of Sfax, 
Tunisia, 2Department of Infectious Diseases, Hedi Chaker Hospital of Sfax, Tunisia and 3Department of Blood Bank, Sfax, Tunisia
Email: Olfa Frikha-Gargouri - Olfafrikha2005@yahoo.fr; Radhouane Gdoura - gdourar@yahoo.com; Abir Znazen - abirznazen2001@yahoo.fr; 
Nozha Ben Arab - nozhabenarab@yahoo.fr; Jalel Gargouri - jalelgargouri@yahoo.fr; Mounir Ben Jemaa - mounir.benjemaa@rns.tn; 
Adnene Hammami* - adnene.hammami@rns.tn
* Corresponding author    
Abstract
Background: Serologic diagnosis of Chlamydophila pneumoniae (Cpn) infection routinely involves
assays for the presence of IgG and IgM antibodies to Cpn. Although IgA antibodies to Cpn have
been found to be of interest in the diagnosis of chronic infections, their significance in serological
diagnosis remains unclear. The microimmunofluorescence (MIF) test is the current method for the
measurement of Cpn antibodies. While commercial enzyme linked immunosorbent assays (ELISA)
have been developed, they have not been fully validated. We therefore evaluated and optimized a
commercial ELISA kit, the SeroCP IgA test, for the detection of Cpn IgA antibodies.
Methods: Serum samples from 94 patients with anti-Cpn IgG titers ≥ 256 (study group) and from
100 healthy blood donors (control group) were tested for the presence of IgA antibodies to Cpn,
using our in-house MIF test and the SeroCP IgA test. Two graph receiver operating characteristic
(TG-ROC) curves were created to optimize the cut off given by the manufacturer.
Results: The MIF and SeroCP IgA tests detected Cpn IgA antibodies in 72% and 89%, respectively,
of sera from the study group, and in 9% and 35%, respectively, of sera from the control group. Using
the MIF test as the reference method and the cut-off value of the ELISA test specified by the
manufacturer for seropositivity and negativity, the two tests correlated in 76% of the samples, with
an agreement of  = 0.54. When we applied the optimized cut-off value using TG-ROC analysis, 1.65,
we observed better concordance (86%) and agreement (0.72) between the MIF and SeroCP IgA
tests.
Conclusion: Use of TG-ROC analysis may help standardize and optimize ELISAs, which are
simpler, more objective and less time consuming than the MIF test. Standardization and
optimization of commercial ELISA kits may result in better performance.
Published: 26 July 2008
BMC Infectious Diseases 2008, 8:98 doi:10.1186/1471-2334-8-98
Received: 25 February 2008
Accepted: 26 July 2008
This article is available from: http://www.biomedcentral.com/1471-2334/8/98
© 2008 Frikha-Gargouri et al; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.BMC Infectious Diseases 2008, 8:98 http://www.biomedcentral.com/1471-2334/8/98
Page 2 of 8
(page number not for citation purposes)
Background
Chlamydophila pneumoniae (Cpn) is a common cause of
acute respiratory infections, primarily pneumonia, as well
as other acute upper and lower respiratory tract infections
such as bronchitis, sinusitis, otitis and pharyngitis. Cpn
infection is associated with 5% to 20% of cases of com-
munity acquired pneumonia in adults and children [1,2].
To date, however, no totally satisfactory serological
method has been developed for the diagnosis of Cpn
infection. The U.S. Centers for Disease Control and Pre-
vention (CDC) has recommended that the microimmun-
ofluorescence (MIF) method be the reference serological
test, despite the poor predictive value of a single high IgG
titer [3].
Diagnosis of acute Cpn infection is based on paired serum
samples obtained 4 to 8 weeks apart showing a 4-fold
increase in IgG antibody titer, or on a single sample show-
ing IgM antibody positivity. IgM antibodies appear earlier
than IgG antibodies, making the former useful for the
rapid diagnosis of acute Cpn infections. The significance
of the presence of chlamydial IgA antibodies for serologi-
cal diagnosis of infection is unclear. The persistence of
these short lived [4] specific IgA antibodies may be a
marker of persistent infection [5], and has been used in
the definition of chronic Cpn infection [6-10]. Studies
have demonstrated an association between specific anti-
Cpn IgA antibodies and several chronic diseases, includ-
ing chronic obstructive pulmonary disease [11], cardio-
vascular disease [12,13], chronic pharyngitis [14] and
chronic upper and lower respiratory tract infections [15].
The reference method for the serological diagnosis of Cpn
infections is the MIF test. This test, however, requires a
highly experienced reader, has several important subjec-
tive components, can be difficult to interpret, and usually
requires both an acute and convalescent specimen to
demonstrate an increase in antibody titer. Furthermore, it
lacks standardization [16]. Due to these drawbacks, sev-
eral partially automated commercial enzyme linked
immunosorbent assays (ELISA) have been developed.
Compared with MIF assays, they are relatively simple to
perform, less time consuming, more objective and easier
to standardize. However, these commercial ELISAs have
not been fully validated. They seem to be less specific but
more sensitive than the MIF test [3]. We therefore evalu-
ated and optimized a commercially available ELISA kit,
the SeroCP IgA test, for anti-Cpn IgA antibodies and com-
pared it with our in house MIF test. This study was not
diagnostic, but rather an assay evaluation, since no conva-
lescent-phase sera were used.
Methods
Sera
Serum samples were obtained from 94 patients referred to
the Department of Infectious Diseases, Hedi Chaker Hos-
pital of Sfax, Tunisia, between January 2002 and Novem-
ber 2004 who had anti-Cpn IgG titers ≥ 256 by our in
house MIF assay (study group). Serum samples were also
obtained from 100 healthy blood donors (90 men; mean
age, 34 years; range, 19–56 years). All serologic assays
were performed by the Laboratory of Microbiology in the
University Hospital of Sfax, Tunisia. All subjects provided
verbal informed consent, and the study protocol was
approved by our ethics committee (Association d'Enregis-
trement et de Lutte Contre le Cancer du Sud Tunisien).
Techniques
MIF test
Cpn species specific IgG and IgA antibodies were meas-
ured by our in house MIF test as described by Wang and
Grayston [17] using as antigens purified elementary bod-
ies of Cpn, IOL-207 strain, Chlamydophila psittaci Loth
strain and Chlamydia trachomatis (Ct) L2 strain. These anti-
gens were produced in yolk sac membranes of infected
eggs. The sacs of uninfected eggs were used as negative
control. The purified elementary bodies were not further
treated (e.g. by removal of lipopolysaccharide). Slides
were prepared as acetone fixed preparations of the puri-
fied antigens by experienced laboratory technicians capa-
ble of maintaining all conditions equal between test runs.
The antigen densities for all experiments were guaranteed
by an optimal concentration of elementary bodies. IgG
antibody titers were determined from serial twofold dilu-
tions of sera, starting at 1/16, and IgA antibody titers were
determined at a single dilution (1:12). Prior to IgA testing,
all sera were absorbed with rheumatoid factor absorbent
(Dade Behring Marburg GmbH) to remove IgG and rheu-
matoid factor interactions according to the manufacturer's
instructions. All MIF series included a positive and a neg-
ative control sample. The slides were incubated with pri-
mary antibody for 30 minutes in a moisture chamber at
37°C, washed twice for 5 minutes each with PBS and
incubated with 1:300 fluorescein isothiocyanate (FITC)
conjugated anti human immunoglobulin (Biorad) for 30
minutes. The mounting fluid for setting coverslips on the
slides contained glycerol in PBS buffer. The next day, the
slides were examined by two experienced and independ-
ent readers using a fluorescent microscope (Zeiss AxioStar
Plus) with × 40 objective. In case of discordant readings,
the slides were assessed by a third reader. Results were
interpreted using the same microscope, by the same read-
ers, at the same time. Only fluorescence with evenly dis-
tributed elementary bodies was scored as a positive
reaction.BMC Infectious Diseases 2008, 8:98 http://www.biomedcentral.com/1471-2334/8/98
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SeroCP-IgA test
The SeroCP™-IgA® test (SeroCP) (Savyon Diagnostics Ltd,
Germany) was used to test for the presence of IgA antibod-
ies to Cpn, following the manufacturer's instructions. The
IgA cut off value (COV) was calculated as twice the mean
absorbance value at 450 nm (A450) of the two negative
controls tested in each run. To normalize the results of dif-
ferent runs, the cut off index for each sample was calcu-
lated as sample A450/COV. The threshold index for a
positive test was 1, as recommended by the manufacturer.
Statistics
All data were collected using standardized forms and ana-
lyzed by Epi-Info version 6. To assess the agreement
between MIF and the SeroCP-IgA test, we used  (nominal
scale variables) [18].  < 0.20 was defined as poor agree-
ment,  = 0.21 to 0.40 as fair agreement;  = 0.41 to 0.60 as
moderate agreement;  = 0.61 to 0.80 as good agreement;
and  = 0.81 to 1.00 as very good agreement. Two-graph
receiver operating characteristic analysis (TG-ROC) [19]
was used to optimize the cut off index of the SeroCP-IgA
test.
Results
Seroprevalence of Cpn IgA antibodies
Using the in house MIF and SeroCP-IgA tests, IgA antibod-
ies to Cpn were detected in 72% (68/94) and 89% (84/
94) of sera from the study group, respectively. Further-
more, Cpn IgA antibody positivity was correlated with
increased Cpn IgG antibody titers (Table 1).
In the control group, the seroprevalence of Cpn IgA anti-
bodies using the in house MIF and SeroCP-IgA tests was
9% (9/100) and 35% (35/100), respectively. Sixty of the
100 healthy blood donors (60%) had IgG anti-Cpn titers
above 1/16 using the MIF test, and five of these sera had
titers above 1/256 and were positive for anti-Cpn IgA anti-
bodies by MIF and ELISA. Of the other 95 sera, with IgG
antibody titers <1/256, 4 were IgA positive by MIF and 30
by ELISA.
Reproducibility of the ELISA test
Reproducibility of the ELISA test was determined by per-
forming assays on the same serum samples, run under the
same conditions, on different days. The differences
between the OD values for sera with low, medium and
high reactivity were each lower than 20% (Figure 1).
Correlation between detection of Cpn IgA antibodies by 
MIF and ELISA before optimization
Using the manufacturer's suggested cut off value, we
observed a concordance of 76% and a moderate agree-
ment ( = 0.54) between the MIF and SeroCP-IgA tests
(Table 2, Figure 2). The concordance between the two
tests was 78% for the study group and 74% for the control
group (Table 2). Using the manufacturer's suggested cut
off value, the agreement between the two tests was fair in
both the study ( = 0.34) and control ( = 0.31) groups. Rel-
ative to the MIF test, the sensitivity and specificity of the
SeroCP-IgA test before optimization were 97.4% and
62.4%, respectively (Table 3).
Optimization of the SeroCP-IgA test
TG-ROC analysis was performed to optimize the cut off
value for the SeroCP-IgA test. The sensitivity and specifi-
city were plotted relative to the MIF results using different
cut-off values (Figure 3), with the one having the highest
sensitivity and specificity utilized. TG-ROC analysis
showed that the optimal cut off index for the SeroCP-IgA
test, relative to the MIF test, was 1.65.
Correlation between detection of Cpn IgA antibodies by 
MIF and ELISA after optimization
Using the optimized cut off value, we observed a concord-
ance of 86% and good agreement ( = 0.72) between the
MIF and SeroCP-IgA tests (Table 2). The concordance was
80% in the study group and 92% in the control group,
with moderate agreement ( = 0.51) between the MIF and
SeroCP-IgA tests in the study group and good agreement (
= 0.62) in the control group. After optimization, the sen-
sitivity and the specificity of the SeroCP-IgA test relative to
the MIF test were 84.4% and 87.2%, respectively (Table
3).
Discussion
We have compared the ability of our in house MIF assay
and a commercial ELISA test to detect serum IgA antibod-
ies to Cpn in patients suspected of having Cpn respiratory
tract infections. Our MIF test was validated using reference
sera and a commercial kit for Cpn (bioMerieux®, France)
(data not shown). Using our MIF test, we found that the
seroprevalence rates of Cpn IgA and IgG antibodies in
healthy Tunisians were 9% and 60%, respectively, similar
to findings in other studies, in which the seroprevalence
rates of anti-Cpn IgA and IgG antibodies ranged from 5%
to 50% and from 35% to 71%, respectively [1,10,12,20-
26]. Thus, assays for IgG antibodies seem to be more sen-
sitive for determining the seroprevalence of anti Cpn anti-
bodies in a healthy population [25,26]. Using the MIF
Table 1: Positivity of IgA antibodies in relation to MIF IgG 
antibodies titers in the study group
MIF IgG  256 512 1024 ≥ 2048
antibodies titers n = 62 n = 16 n = 7 n = 9
MIF IgA + (%) 41 (66) 12 (75) 6 (85) 9 (100)
ELISA IgA + (%) 57 (86) 15 (94) 7 (100) 9 (100)BMC Infectious Diseases 2008, 8:98 http://www.biomedcentral.com/1471-2334/8/98
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Reproducibility of the SeroCP IgA ELISA assay Figure 1
Reproducibility of the SeroCP IgA ELISA assay. ODs at 450 nm were obtained from two ELISA tests conducted on the 
same serum samples on two different days. The differences between OD 450 nm values were less than 20%.
Table 2: Correlations between the detection of Cpn IgA antibodies by MIF and ELISA
Before optimization After optimization








n = 194 n = 94 n = 100 n = 194 n = 94 n = 100
+/+ 75 66 9 65 57 8
-/- 73 8 65 102 18 84
+/- 22 0 1 2 1 1 1
-/+ 44 18 26 15 8 7
Concordance (%) 76 78 74 86 80 92
0.54 0.34 0.31 0.72 0.51 0.62BMC Infectious Diseases 2008, 8:98 http://www.biomedcentral.com/1471-2334/8/98
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test, we observed a correlation between anti-Cpn IgA sero-
positivity and IgG titers, confirming previous results [27].
The performance of ELISA assays for anti-Cpn antibodies
have been compared relative to the results of the MIF test,
considered the standard method for the diagnosis of Cpn
infections [25,28-30]. We focused on the SeroCP ELISA
test, as its results more closely correlated with the results
of MIF tests than did the results of other commercial diag-
nostic kits [31]. Our findings confirm that the SeroCP-IgA
test was reproducible [32]. Before optimization, however,
the correlation between the MIF and ELISA tests in detect-
ing anti-Cpn IgA antibodies was not sufficient and the
results of the two showed only moderate agreement. Our
results are in agreement with those comparing the
SeroCP-IgA test with a commercial MIF assay (Labsys-
tems) [31]. In addition, we found that the SeroCP IgA
ELISA test detected anti-Cpn IgA antibodies in samples
that were negative by our in house MIF test. This finding
agrees with results showing that the Labsystems IgA ELISA
test also overestimated the prevalence of IgA antibodies
(62%) compared with MIF (26%) [33]. Similar findings
were reported for the detection of IgG antibodies by dif-
ferent serological methods [34].
The discrepancies between MIF and ELISA in the detection
of anti-Cpn IgA antibodies may have been due to the dif-
ferent experimental conditions used in the two serological
tests, including the Cpn strains, incubation times, antigen
concentrations, serum dilutions, absorption experiments
and the types of conjugates used.
Table 3: Performance of the SeroCP IgA ELISA test before and after optimization
Before optimization After optimization








Sensitivity (%) 97.4 97.1 100 84.4 83.8 88.9
Specificity (%) 62.4 30.8 71.4 87.2 69.2 92.3
PPV (%) 63.0 78.6 25.7 81.3 87.7 53.3
NPV (%) 97.3 80.0 100 89.5 62.1 98.8
PPV: Positive predictive value, NPV: Negative predictive value
Distribution of SeroCP IgA index in relation to MIF IgA antibody seropositivity Figure 2
Distribution of SeroCP IgA index in relation to MIF IgA antibody seropositivity. a, Distribution of SeroCP IgA 
index in relation to MIF IgA antibody seropositivity in the study group. b, Distribution of SeroCP IgA index in relation to MIF 
IgA antibody seropositivity in the control group. The continuous lines are the manufacturer's cut off indices, and the discontin-
uous lines are the optimized cut off values.BMC Infectious Diseases 2008, 8:98 http://www.biomedcentral.com/1471-2334/8/98
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Since both the SeroCP test and our MIF test use purified
elementary bodies of Cpn as antigen, both assays measure
antibodies directed against antigens localized on the sur-
face of Cpn elementary bodies. However, the SeroCP test
uses TWAR 183 as the reference strain, whereas our in
house MIF uses the IOL-207 strain. Immunoblot analyses
have detected antigenic differences between Cpn strains
[35], and an MIF analysis of the antigenic profiles of six
Cpn strains found that serum samples from culture posi-
tive patients had 4–8 fold higher titers against autologous
strains than against TW-183 [36]. Furthermore, the crite-
ria for establishing a diagnosis of acute infection were met
only by the antigen from the local strain, not by TW-183.
Thus, the serologic diagnosis of Cpn infection may require
the use of antigens from more than one Cpn strain. In
contrast, a comparison of the performance of three com-
mercial MIF assays (WRF, Labsystems and MRL), which
use different Cpn strains as antigens, found that their IgA
endpoint titers were similar [37].
Increased incubation time and antigen concentration
have been found to increase the sensitivity of the Labsys-
tems MIF test to detect anti-Cpn IgA antibodies [38]. Our
and commercial MIF tests have an incubation time of 30
minutes, whereas the SeroCP IgA test has an incubation of
1 hour. Furthermore, our in house MIF test uses an opti-
mal concentration of elementary bodies, which was cali-
brated using the commercial MIF test and reference sera.
In addition, the SeroCP-IgA test used a higher dilution
(1:105) than the MIF test (1:12), which may affect agree-
ment between the methods [31]. This prozone effect with
higher dilution of antibodies is supported by findings
showing that the agreement between the MIF and ELISA
tests was adequate at low but not at high titers and that the
sensitivity of the ELISA test could be increased by testing
sera with elevated titers at higher dilutions [39]. The man-
ufacturer instructions for the SeroCP IgA test contain no
data regarding the use of rheumatoid factor absorption.
Absence of preabsorption experiment in the ELISA test
may have increased the rate of false positive results, due to
IgG interference.
One drawback to the measurement of anti-Cpn IgA anti-
bodies may be the considerable variation in commercial
anti-IgA conjugates, which may hamper the accurate
detection of IgA antibodies [40,41]. In a comparative
study of the IgA titers and seroconversions using six fluo-
rescein anti-human IgA conjugates, only one of 14 sero-
conversions was detected by all 6 conjugates and in most,
only one of the conjugates showed a significant increase
in titer [40].
The discordance between MIF and ELISA may also be
related to the increased sensitivity of the ELISA tests
[26,33]. We found that the sensitivity of the SeroCP-IgA
test, relative to our MIF test, was high before optimization
(97.4%), but its specificity was limited (62.4%). Using the
same antigen, we previously found that the specificity of
the SeroCP IgG antibodies was 38.5% and that this test
was not sufficiently specific to distinguish between IgG
antibodies to Cpn and to Ct [29]. The MIF test is regarded
internationally as the standard method for the determina-
tion of Chlamydia seropositivity [3]. Thus, the high sensi-
tivity of ELISA tests could be interpreted in the reverse
direction; rather, the specificity of the ELISA may be lower
than that of the MIF test [42].
Although the MIF test is the currently recommended
method for the measurement of Cpn antibodies [3] and is
used in most clinical studies, this test is time consuming
and requires skilled personnel for interpretation of the
slides. Furthermore, its specificity has been questioned
due to cross-reactions between chlamydial species
[29,43]. Its ability to detect cross-reacting antibodies is
not surprising because it detects antibodies against surface
protein antigens of elementary bodies, which are shared
by chlamydial species and other Gram negative bacteria
[44-46]. In contrast to MIF, ELISAs are relatively simple,
less time consuming, and more objective as they rely on
photometric reading and are therefore easier to standard-
ize. However, ELISA is relatively unreliable for Cpn anti-
bodies detection compared with MIF [47]. Using ROC
analysis in patients with coronary heart disease; the
SeroCP-IgG test was found to correlate well against a com-
mercial MIF assay (Labsystems), with the optimized cut
TG-ROC analysis of the SeroCP-IgA test in sera from study  and control groups Figure 3
TG-ROC analysis of the SeroCP-IgA test in sera from 
study and control groups. The vertical line represents the 
suggested cut off value (1.65). Sn: sensitivity, Sp: specificity.BMC Infectious Diseases 2008, 8:98 http://www.biomedcentral.com/1471-2334/8/98
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off value corresponding to that recommended by the
manufacturer [31]. In our study, we focused only on
SeroCP-IgA antibodies as they have been found to gener-
ate a moderate concordance when compared to the MIF
test [29,31]. Sera from healthy blood donors were used in
our study in order to determine the prevalence of Cpn IgG
and IgA antibodies and also to optimize the SeroCP IgA
test. We found that only 9 out of these 100 sera were pos-
itive for IgA antibodies. Accurate optimization of the
SeroCP IgA test required a homogeneous distribution of
IgA antibodies in the serum samples. In addition, since
our patients were clinically suspected of Cpn infection, we
chose samples with IgG titers ≥ 256 instead of ≥ 512 to
maximize the number of samples positive for IgA anti-
bodies. When we used TG-ROC analysis to optimize the
SeroCP IgA test in comparison to our MIF test, we found
that test characteristics depended on the cut off value.
Rather than using the cut off value recommended by the
manufacturer, we estimated a new cut off value from the
TG-ROC analysis to optimize the discrimination between
positive and negative results [19]. TG-ROC analyses plot
sensitivity and specificity as a function of cut off, with the
cut-off value that optimized sensitivity and specificity uti-
lized (1.65). Using this cut off index, we found a better
concordance and agreement between the MIF and the
SeroCP-IgA tests. If agreement between serologic tests is
high, there should be no problems using either [34]. We
found that, using our optimized cut off value, the sensitiv-
ity and specificity of the SeroCP-IgA test were 84.4% and
87.2%, respectively. Both sensitivity and specificity were
higher in the control than in the study group, confirming
results showing that the correlation between the MIF and
SeroCP IgA tests was better with sera negative than posi-
tive for anti-Cpn IgA antibodies [39].
Conclusion
The results of our study indicate that a high proportion of
patients with anti-Cpn IgG titers ≥ 256 were positive for
anti-Cpn IgA antibody. In comparing the SeroCP-IgA test
with the MIF method, we found that the optimal cut off
index for the SeroCP-IgA test was 1.65. TG-ROC analysis
may provide an approach to the standardization and opti-
mization of ELISAs, which are simpler, more objective
and less time consuming than MIF tests. However, their
difference in detecting anti-Cpn IgA antibodies suggests
that the MIF continues to be the standard method for their
measurement. Standardization and optimization of com-
mercial ELISA tests, relative to the MIF test, may enhance
the performance of the former.
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